

March 27, 2019

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

Code : **532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

Code: **CADILAHC**

Re.: Press Release.

Dear Sir / Madam,

Please find enclosed a copy of press release dated March 27, 2019 titled "Zydus scores with the Day 1 launch of Tadalafil Tablets in the US".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus scores with the Day 1 launch of Tadalafil Tablets in the US**

*Ahmedabad, 27 March, 2019*

Zydus Cadila announced the Day 1 launch of Tadalafil Tablets USP (US RLD – Cialis Tablets) upon receiving the final approval from the US FDA for marketing the product in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Manufactured at the group's manufacturing facility at Moraiya, Ahmedabad, the drug is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate).

The sales of Tadalafil Tablets USP in the US stood at \$1.73 billion. *(As per IQVIA, National Sales Perspective Audit, MAT January 2019)*

The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*